Hagop Youssoufian
Treos Bio Ltd. · Verastem, Inc.
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
25
all conditions, ClinicalTrials.gov
NIH grants tied to them
0
4 more share only the name and are not shown
Trial papers
24
PubMed author-name match
Trials
Studies that name Hagop Youssoufian as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:30 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05243862 · Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.Treos Bio Limited · completed · Colorectal Cancer Metastatic · study director
- Ph1NCT02943317 · Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian CancerVerastem, Inc. · terminated · Epithelial Ovarian Cancer · study chair
- Ph1NCT02913716 · A Phase I, Open-label Study of Absorption, Metabolism, and Excretion of Defactinib (VS-6063) in Healthy Male SubjectsVerastem, Inc. · completed · Healthy Subjects · study chair
- Ph1NCT02651727 · Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer SubjectsVerastem, Inc. · terminated · Pancreatic Cancer · study chair
- Ph2NCT02605694 · Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)SecuraBio · withdrawn · Lymphoma · study chair
- Ph3NCT02576275 · A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)SecuraBio · withdrawn · Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma, Small Lymphocytic Lymphoma · study chair
- Ph1/Ph2NCT02391545 · A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)SecuraBio · terminated · CD20+ Follicular Lymphoma · study chair
- Ph1NCT02372227 · A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant MesotheliomaVerastem, Inc. · terminated · Relapsed Malignant Mesothelioma · study chair
- Ph1NCT02307461 · Bioequivalence of Duvelisib and Food Effect on Pharmacokinetics of IPI-145SecuraBio · completed · Healthy · study chair
- Ph1NCT02215629 · Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic LeukemiaVerastem, Inc. · withdrawn · Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia · study chair
- Ph3NCT02204982 · Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular LymphomaSecuraBio · terminated · Follicular Lymphoma · study chair
- Ph1NCT02095587 · Duvelisib in Hepatically Impaired Subjects Compared to Healthy SubjectsSecuraBio · completed · Hepatic Impairment · study chair
- Ph3NCT02049515 · A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07SecuraBio · completed · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma · study chair
- Ph1NCT01991938 · Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or LymphomaVerastem, Inc. · terminated · Non Hematologic Cancers, Metastatic Cancer, Lymphoma · study chair
- Ph1NCT01947777 · Phase 1 Study in Healthy Subjects to Evaluate the Effect of Rifampin on the Pharmacokinetics of IPI-145SecuraBio · completed · Healthy · study chair
- Ph1NCT01943292 · Phase I Dose Escalation Study of VS-6063 in Japanese Subjects With Non-Hematologic MalignanciesVerastem, Inc. · completed · Non Hematologic Cancers · study chair
- Ph1NCT01925911 · Phase 1 Study in Healthy Subjects to Evaluate the Effect of IPI-145 on the Pharmacokinetics of MidazolamSecuraBio · completed · Healthy · study chair
- Ph2NCT01870609 · Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural MesotheliomaVerastem, Inc. · terminated · Malignant Pleural Mesothelioma · study chair
- Ph2NCT01851707 · A Double-Blind Study Evaluating Duvelisib in Subjects With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate AloneSecuraBio · completed · Rheumatoid Arthritis · study chair
- Ph1NCT01849744 · Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic MalignanciesVerastem, Inc. · terminated · Non Hematologic Cancers, Metastatic Cancer · study chair
- Ph1NCT01836861 · IPI-145 ADME and Absolute Bioavailability StudySecuraBio · completed · Healthy · study chair
- Ph1NCT01778803 · Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian CancerVerastem, Inc. · completed · Ovarian Cancer · study chair
- Ph2NCT01653756 · A Phase 2a, Efficacy and Safety Study of Duvelisib in Mild Asthmatic SubjectsSecuraBio · completed · Asthma · study chair
- Ph1NCT01549106 · IPI-145 Single Ascending, Multiple Ascending, Food Effect and Drug-Drug-Interaction StudySecuraBio · completed · Healthy Volunteers · study chair
- Ph1NCT01476657 · A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic MalignanciesSecuraBio · terminated · Hematologic Malignancies · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:30 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 4 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 09:30 UTC. The ranking covers the 200 most relevant of 24 PubMed records, and a shared surname and initials can bring in a namesake. All 24 on PubMed
- 3,947 citationsRCR 94.9
- 1,466 citationsRCR 38.8
- 473 citationsRCR 10.8
- Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors.Clin Cancer Res · 2016215 citationsRCR 8.1
- 199 citationsRCR 7.7
- 115 citationsRCR 2.6
- 82 citationsRCR 2.3
- A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies.Clin Cancer Res · 201078 citationsRCR 1.7
- Clinical and Translational Results of a Phase II, Randomized Trial of an Anti-IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy.Clin Cancer Res · 201663 citationsRCR 1.9
- Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201.J Clin Oncol · 202559 citationsRCR 12.6